Variability of the dietary-derived CYP2D6 activity marker solanidine in vivo

被引：0
|
作者：
Mueller, J. P. [1 ]
Saromba, J. [1 ]
Ziegler, P. [2 ]
Tremmef', R. [3 ,4 ]
Rengelshausen, J. [2 ]
Schaeffeler, E. [3 ,4 ]
Just, K. S. [1 ]
Schwab, M. [3 ,5 ,6 ]
Kraus, T. [2 ]
Sting, J. C. [1 ]
机构：
[1] Univ Hosp RWTH Aachen, Inst Clin Pharmacol, Aachen, Germany
[2] Univ Hosp RWTH Aachen, Inst Occupat Social & Environm Med, Aachen, Germany
[3] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany
[4] Univ Tubingen, Tubingen, Germany
[5] Univ Tubingen, Dept Clin Pharmacol, Tubingen, Germany
[6] Univ Tubingen, Dept Biochem & Pharm, Tubingen, Germany
来源：
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY | 2024年 / 397卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P226
引用
收藏
页码：S72 / S72
页数：1
相关论文
共 50 条
  • [41] The effects of Puerarin on CYP2D6 and CYP1A2 activities In vivo
    Jiao Zheng
    Bin Chen
    Bing Jiang
    Ling Zeng
    Zhi-Rong Tang
    Lan Fan
    Hong-Hao Zhou
    Archives of Pharmacal Research, 2010, 33 : 243 - 246
  • [42] GENETIC POLYMORPHISM IN CYTOCHROME P450 2D6 (CYP2D6): POPULATION DISTRIBUTION OF CYP2D6 ACTIVITY
    Neafsey, Patricia
    Ginsberg, Gary
    Hattis, Dale
    Sonawane, Babasaheb
    JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART B-CRITICAL REVIEWS, 2009, 12 (5-6): : 334 - 361
  • [43] Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6
    Livezey, Mara R.
    Briggs, Erran D.
    Bolles, Amanda K.
    Nagy, Leslie D.
    Fujiwara, Rina
    Furge, Laura Lowe
    XENOBIOTICA, 2014, 44 (04) : 309 - 319
  • [44] Assessment of CYP2D6 activity in depressed patients
    Szewczuk-Bogusawska, M
    Orzechowska-Juzwenko, K
    Milejski, P
    Beszlej, JA
    Grzesiak, M
    Kiejna, A
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S219 - S219
  • [45] Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR
    Hersberger, M
    Marti-Jaun, J
    Rentsch, K
    Hänseler, E
    CLINICAL CHEMISTRY, 2000, 46 (08) : 1072 - 1077
  • [46] CYP2D6 activity in methadone maintenance patients
    Shiran, MR
    Rostami-Hodjegan, A
    Lennard, MS
    Iqbal, MZ
    Lagundoye, O
    Pratt, P
    Seiveright, N
    Tucker, GT
    JOURNAL OF PSYCHOPHARMACOLOGY, 2002, 16 (03) : A54 - A54
  • [47] The use of Yohimbine for phenotyping of CYP2D6 activity
    Vay, M.
    Rose, P.
    Meyer, M.
    Mikus, G.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2019, 392 : S24 - S24
  • [48] Catalytic in vivo function of CYP2D6 in relation to the genotype
    Griese, EU
    Gaedigk, A
    Morike
    Mikus, G
    Zanger, U
    Eichelbaum, M
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1997, 355 (04) : 458 - 458
  • [49] More data for the CYP2D6 hypothesis?:: The in vivo inhibition of CYP2D6 isoenzyme and extrapyramidal symptoms induced by antidepressants in the elderly
    García-Parajuá, P
    de Ugarte, L
    Baca, E
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2004, 24 (01) : 111 - 112
  • [50] Interrogation of CYP2D6 Structural Variant Alleles Improves the Correlation Between CYP2D6 Genotype and CYP2D6-Mediated Metabolic Activity
    Dalton, Rachel
    Lee, Seung-been
    Claw, Katrina G.
    Prasad, Bhagwat
    Phillips, Brian R.
    Shen, Danny D.
    Wong, Lai Hong
    Fade, Mitch
    McDonald, Matthew G.
    Dunham, Maitreya J.
    Fowler, Douglas M.
    Rettie, Allan E.
    Schuetz, Erin
    Thornton, Timothy A.
    Nickerson, Deborah A.
    Gaedigk, Andrea
    Thummel, Kenneth E.
    Woodahl, Erica L.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (01): : 147 - 156
12345